TNFRSF8 and classic Hodgkin lymphoma: Although the treatment of patients with cHL has improved with the combination or the sequential use of drugs targeting CD30 [such as the anti-CD30 monoclonal antibody conjugated with the monomethyl auristatin E (MMAE) brentuximab vedotin] and immune checkpoint PD-1 inhibitors (such as pembrolizumab and nivolumab) with chemotherapy, the outcome of double or triple refractory patients is still poor.